Cadwalader Represents Salix Pharmaceuticals in Its Acquisition by Valeant Pharmaceuticals

April 01, 2015

Cadwalader represented Salix Pharmaceuticals, Ltd., a leading U.S. specialty pharmaceutical company, in its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) for $173.00 per share, or a total enterprise value of approximately $15.6 billion.  The transaction was completed on April 1, 2015.

Cadwalader has advised Salix in connection with various governance, litigation and transactional matters, including its terminated combination with Cosmo Technologies.

The Cadwalader team is led by Christopher Cox and includes Corporate partners Gregory Patti, Jr., William Mills and Ira Schacter, Corporate associates Anita Wong and Alexandra Cotter; Tax partner Linda Swartz; Intellectual Property partner Dorothy Auth; and Finance partner Jeff Nagle.

About Cadwalader, Wickersham & Taft LLP

Cadwalader, Wickersham & Taft LLP, established in 1792, serves a diverse client base, including many of the world's leading financial institutions and corporations in more than 50 countries. With offices in New York, London, Charlotte, Washington, Houston, Beijing, Hong Kong and Brussels, Cadwalader offers legal expertise in antitrust, banking, corporate finance, corporate governance, energy, environmental, executive compensation, financial restructuring, health care, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance, tax and white collar defense. For more information, visit

About Salix Pharmaceuticals, Ltd.  

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.